SSSotaro Sadahiro

Sotaro Sadahiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sotaro Sadahiro has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Chieko Murayama

    Department of Radiology, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    2 shared publications
  • Hiroyasu Makuuchi

    Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    2 shared publications
  • Seiei Yasuda

    Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    2 shared publications
  • Tomoo Tajima

    Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    2 shared publications
  • Toshiyuki Suzuki

    Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    2 shared publications
  • Kenji Ishikawa

    Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    1 shared publication

Latest Publications

  • Open Access

    Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma

    by Sotaro Sadahiro, Toshiyuki Suzuki, Kenji Ishikawa, Seiei Yasuda, Tomoo Tajima, Hiroyasu Makuuchi, Takuro Saitoh, Chieko Murayama

    BACKGROUND: The liver is the most frequent site of recurrence after curative resection in patients with colon carcinoma. For liver metastasis, a high response rate can be achieved with hepatic arterial infusion (HAI) chemotherapy. In the current study, the authors administered 5‐fluorouracil (5‐FU) as adjuvant chemotherapy by HAI to patients with colon carcinoma without liver metastases and studied its effects on recurrence in the liver and survival.METHODS: A total of 316 patients with preoperative Stage II or Stage III colon carcinoma (according to the 1997 revision of the International Union Against Cancer TNM staging system) were randomly assigned to receive surgery plus 3‐week continuous HAI of 5‐FU or surgery alone. There were 305 eligible patients, of whom the 119 patients assigned to the HAI arm actually received 5‐FU. The primary endpoint was disease‐free survival, whereas the secondary endpoints were overall survival and liver metastasis‐free survival. Analysis was by intent to treat.RESULTS: There were no significant differences noted in morbidity between the two treatment arms. During the follow‐up period (median, 59.0 months), the incidence of liver metastasis was significantly decreased in the HAI arm whereas there were no significant differences reported between the 2 arms with regard to the frequency of metastasis at other sites. In the HAI arm, the risk ratio for recurrence was 0.40 (95% confidence interval [95% CI], 0.24–0.64; P = 0.0002), the risk ratio for death was 0.37 (95% CI, 0.21–0.67; P = 0.0009), and the risk ratio for liver metastasis was 0.38 (95% CI, 0.22–0.66; P = 0.0005). These differences were found to be significant only for patients with Stage III disease. Toxicities were mild.CONCLUSIONS: A schedule of 3‐week HAI of 5‐FU given as adjuvant chemotherapy to patients with Stage III colon carcinoma appeared to contribute to a significant decrease in the frequency of liver metastases and was associated with an improved survival rate. Cancer 2004. © 2003 American Cancer Society.


  • Open Access

    Detection of tumor cells in the portal and peripheral blood of patients with colorectal carcinoma using competitive reverse transcriptase-polymerase chain reaction

    by Sotaro Sadahiro, Toshiyuki Suzuki, Nobuhiro Tokunaga, Satoshi Yurimoto, Seiei Yasuda, Tomoo Tajima, Hiroyasu Makuuchi, Chieko Murayama, Koichiro Matsuda

    BACKGROUND In spite of many reports, it remains unclear whether the presence of tumor cells in circulating blood flow predicts a poor prognosis. METHODS Competitive seminested reverse transcriptase‐polymerase chain reaction (RT‐PCR), a technique for the quantitative detection of tumor cells, was applied to detect the presence of tumor cells in portal and peripheral blood samples from 121 patients with colorectal carcinoma and to clarify their clinical significance. This technique can detect one carcinoembryonic antigen (CEA) mRNA‐expressing tumor cell in 1 × 105 normal lymphocytes. RESULTS Six of 33 healthy volunteers (18%) demonstrated a positive reaction to this technique. CEA mRNA expression was detected in the portal blood in 51% of patients and in the peripheral blood in 42% of patients. The results from the two blood samples were consistent in 91% of patients. The positive expression rates for portal blood in patients with T1 tumors and those with TNM Stage I disease were 38% and 45%, respectively. The positive rate was significantly higher in patients with colon carcinoma and those with Stage III or IV disease. CEA mRNA expression, quantitatively measured (× 10−8/β‐actin), was 22.9 ± 35.1 in the portal blood and 19.9 ± 40.0 in the peripheral blood, with no statistically significant difference. A significant positive correlation was noted between portal and peripheral CEA mRNA expression levels according to Speaman correlation analysis (correlation coefficient = 0.78; P < 0.01). Multivariate analysis revealed that the positive rate and level of CEA mRNA expression in the portal and peripheral blood did not appear to be influenced by the established prognostic factors. CONCLUSIONS The presence of circulating tumor cells might be of less value as a prognostic factor because they also can be detected in patients with early‐stage colorectal carcinoma and appeared to be independent of the conventional prognostic factors. Cancer 2001;92:1251–58. © 2001 American Cancer Society.